MAP‐AD Test robustness for blood mitochondrial methylcytosines measurement
The MAP-AD Test is an accurate and reliable tool, as demonstrated by the results of its analytical validation. This is the first epigenetic IVD Test for the prognosis of ADD and highly contributes to approaching AD in a holistic manner towards personalized medicine global AD strategy, along with new therapies and biomarkers development.
Authors
- Víctor Andrade (ORCID: https://orcid.org/0000-0003-0682-269X)
- Carla Trapero (ORCID: https://orcid.org/0000-0001-7948-8122)
- Marta Blanch (ORCID: https://orcid.org/0000-0003-1913-0158)
- José Luis Mosquera
- Beatriz Fontal
- Pau Martí
- Marta Barrachina
Institutions
- RMIT Europe (ES)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_098536
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.00